You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
生物疫苗概念股再度走強 魯抗醫藥等多股連續漲停
格隆匯1月21日丨生物疫苗概念股再度走強,魯抗醫藥、萬孚生物、萊茵生物、達安基因等多股連續漲停。

廣東省衞健委官方微博1月20日晚通報,確認廣東省昨日新增13例新型冠狀病毒感染的肺炎確診病例。截至20日20時,我國境內累計確診新型冠狀病毒肺炎病例218例(武漢198例,北京5例,廣東14例,上海1例)。新增病例分佈如下:深圳8例、珠海3例、湛江、惠州各1例,均收治在當地定點醫療機構隔離治療。1月20日晚,國家衞生健康委確認上海市首例輸入性新型冠狀病毒感染的肺炎確診病例。
截止目前,已有十餘家公司在公告、微博、互動易上對冠狀病毒相關預防產品做出迴應。碩世生物、華大基因、科華生物、西隴科學、達安基因明確表示公司已有冠狀病毒測試劑盒研發成果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.